Overview
KLRS market data
Price History
KLRS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for KLRS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Kalaris Therapeutics, Inc. (KLRS)SEC EDGAR · Jul 20, 2026, 12:07 PM
Kalaris Therapeutics Appoints Liisa Bayko CFOBenzinga · Jul 20, 2026, 12:03 PM
Why Is Kalaris Therapeutics Stock Gaining Friday?Benzinga · Jul 17, 2026, 5:31 PM
Kalaris Therapeutics shares are trading higher after the company announced additional data from its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration.Benzinga · Jul 17, 2026, 2:58 PM
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD CohortsGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Kalaris Therapeutics Announces Additional Data From Its Phase 1A Trial Of TH103 In Neovascular Age-Related Macular Degeneration; Additional Patients Showed Improvements In Vision And Retinal AnatomyBenzinga · Jul 17, 2026, 11:05 AM
Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027Benzinga · Jul 17, 2026, 11:02 AM
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively EnrollingGlobenewswire Inc · Jun 23, 2026, 12:15 PM
Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing PatientsBenzinga · Jun 23, 2026, 12:15 PM
TD Cowen Initiates Coverage On Kalaris Therapeutics with Buy RatingBenzinga · Jun 15, 2026, 4:50 PM